Clinical trials: FAPI
Breast Cancer, Invasive Breast Cancer
A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer
The purpose of this study is to find out whether it is practical (feasible) to use a new type of imaging scan called 68Ga-FAPI PET/MRI (positron emission tomography/magnetic resonance imaging) to evaluate how well breast cancer…
- Trial name
- NCT07899892
- Testing
- 68Ga-FAPI-PET/MRI
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Histiocytosis
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
Histiocytic disorders are rare diseases that are characterized by tissue infiltration of histiocytes (dendritic cells) and other inflammatory white blood cells.68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast…
- Trial name
- NCT05803629
- Testing
- 68Ga-FAPI, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Atherosclerosis
68Ga-FAPI PET/MR for Atherosclerosis
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially…
- Trial name
- NCT05036759
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer
A study to discuss the advantage of Fapi PET- CT in the initial diagnosis staging and lesion determination of ovarian cancer,whether it can be a evaluation strategy as an R0 evaluation tool or a prediction tool of chemotherapy…
- Trial name
- NCT05824247
- Testing
- 68Ga-FAPI-PET-CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hepatocellular Carcinoma (HCC)
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
- Trial name
- NCT06746194
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Lung Cancer
Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer
This is a prospective, single-center, single arm, open label study to evaluate the performance of 68Ga-FAPI-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18F-FDG PET.
- Trial name
- NCT05617742
- Testing
- 68Ga-FAPI-46
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Chang Gung Memorial Hospital
Carcinoma, Intraductal, Noninfiltrating
Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer
DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET/MRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast…
- Trial name
- MI-CISDIR (NCT06540872)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Cancer
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Positron Emission Tomography (PET) is a functional imaging technology for diagnosing and monitoring tumors. In clinical applications for malignant tumors, PET includes staging, response assessment, and prognosis prediction…
- Trial name
- NCT07128277
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Crohn Disease
Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn's Disease
Crohn's Disease (CD) is a chronic inflammatory condition that can affect any part of the intestine and currently has no cure. It affects 6.8 million people worldwide with UK healthcare costs in excess of £1 billion per year.
- Trial name
- FATE-CD (NCT07152431)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Edinburgh
Vulvar Squamous Cell Carcinoma
In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer
This study aims to investigate the expression of FAP by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. This in vitro study will include all consecutive tumour specimens stored both in optimal cutting…
- Trial name
- FAPI_VULVA_1 (NCT06911801)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Rationale and Trial Design of PFB-03 Study: Diagnostic Performance and Clinical Application of 18F-FAPI-PET/CT for Detecting Axillary Lymph Node Metastasis in Breast Cancer Patients After Neoadjuvant Therapy
Axillary lymph node (ALN) status is a crucial prognostic factor in breast cancer. Accurate, non-invasive methods for evaluating axillary lymph node metastasis after neoadjuvant therapy (NAT) are needed to optimize surgical…
- Trial name
- NCT07012707
- Volunteers
- 172 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Tumors, Positron-Emission Tomography
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors.
- Trial name
- NCT06270394
- Testing
- 68Ga-Fibroblast activation protein inhibitor
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Pancreatic Cancer, Adult, Gastroesophageal Cancer (GC)
BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
The goal of this clinical trial is to learn if [68Ga]Ga-FAPI-46 Total Body PET/CT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer.
- Trial name
- BEFAST (NCT07629609)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Barbara Malene Fischer
SAPHO Syndrome
Characterizing SAPHO With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation.
- Trial name
- NCT04596462
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer, Hepatocellular Carcinoma
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors.
- Conditions
- Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors
- Trial name
- NCT07639801
- Testing
- 68Ga-FAPI-PSMA, 68Ga-PSMA-617, 68Ga-FAPI-04
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Interstitial Lung Disease
Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease
The goal of this observational study is to examine clinical utility of 18F-FAPI-RGD PET/CT imaging in evaluating connective tissue disease-associated interstitial lung disease.
- Trial name
- NCT06143540
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Provincial People's Hospital
Tumor
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers.
- Trial name
- NCT06740240
- Testing
- 68Ga-FAPI-Biotin, 68Ga-FAPI/18F-FDG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Nonischemic Cardiomyopathy
FAPI PET Imaging in Nonischemic Cardiomyopathy
This study aims to evaluate the clinical value of [¹⁸F]AlF-NOTA-FAPI-04 PET/CT for the noninvasive assessment of myocardial fibroblast activation in patients with nonischemic cardiomyopathy.
- Trial name
- FAPI-NICM (NCT07878338)
- Testing
- [¹⁸F]AlF-NOTA-FAPI-04
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED).
- Trial name
- NCT07423013
- Testing
- [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Peritoneal Metastasis, Gastric Cancer
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
- Trial name
- NCT06597526
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital